Website intended for a NZ health professional readership
This article discusses a case of minocycline-induced facial hyperpigmentation with later nail involvement
1. Martins AM, Marto JM, Johnson JL, Graber EM. A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea. Antibiotics (Basel) 2021;10(7):757.
2. Eisen D, Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. Drug Saf 1998;18(6):431–40.
3. Shute L, Walkty A, Embil JM. Minocycline-induced cutaneous hyperpigmentation. CMAJ 2020;192(34):E981.
4. Ahmad Y, Boutros H, Hanna K. Out of the blue: A case of blue subungual discoloration associated with prolonged tetracycline use. Cureus 2020;12(4):e7810.
5. Varghese K, Dykstra J, Bisbee E. Minocycline-induced hyperpigmentation of nails. Cureus 2023;15(5):e38640.
6. Ricardo JW, Shah K, Minkis K, Lipner SR. Blue skin, nail, and scleral pigmentation associated with minocycline. Case Rep Dermatol 2022;14(2):239–42.
7. Adib F, Wong J, Loftu R. Blue nails: a case of minocycline-induced hyperpigmentation. World Allergy Organization Journal 2020;13(8):100255.
8. Dalby C. A man with blue-grey nails. Aust J Gen Pract 2021;50(3):148–50.
9. Sujaya SN, Ranganath VS, Girish BS, et al. Topical minocycline induced bluish black hyperpigmentation in acne vulgaris patient: The first case report of topical application. JDDT 2024;14(4):4–6.
10. Wang RF, Ko D, Friedman BJ, et al. Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders. J Am Acad Dermatol 2023;88(2):271–88.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
